NicoBloc

Nicotine-free fluid alternative to conventional NRT products is now available in the U.S., Rosen Holdings announces Nov. 19. Product has been available in the UK, Ireland, New Zealand and Australia. NicoBloc "is a clinically proven" smoking reduction method that slowly alleviates smokers' nicotine addiction "by blocking the tar and nicotine inhaled and [letting] them quit at their own pace." Smokers using the three-stage, six-week NicoBloc program drop the fluid on cigarettes to trap tar and nicotine; one drop traps 33% of the harmful substances, according to Rosen. Smokers may choose to be "smoke-free in as little as" one week, since consumers can set their own quitting pace, the Plymouth, Mass.-based firm maintains. NicoBloc bottles contain enough fluid for one pack of cigarettes. The product retails for $39.99 at Eckerd and online at drugstore.com...

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

What Pharma Needs To Know About Vietnam’s Drug Registration Reforms

 

Newly introduced rules for streamlining drug registration in Vietnam are said to present both opportunities and challenges for stakeholders.

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By 

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

England’s NHS Plan Eyes Cancer Vaccine Boost, Single Formulary & ‘Pay For Impact’ Drug Deal

 

The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.